Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Realistic Goals of Stem Cell Therapy for MS: Fatigue, Mobility, and Relapse Rate
Transcript
- 0:00SPEAKER_01: Welcome to the Cyrona Cell Podcast.
- 0:02SPEAKER_01: Imagine for a moment that your body is a house, right.
- 0:05SPEAKER_01: And your immune system is this like state-of-the-art security system you installed to keep all the bad guys out.
- 0:12SPEAKER_00: Right.
- 0:12SPEAKER_00: The ultimate defense mechanism.
- 0:14SPEAKER_01: Exactly.
- 0:15SPEAKER_01: But now imagine waking up one day to find that your own security system has suddenly locked all the doors, turned on the sirens, and uh it's literally started setting fire to the electrical wiring inside your own wall.
- 0:28SPEAKER_00: Wow.
- 0:28SPEAKER_00: Yeah.
- 0:29SPEAKER_00: And for millions of people living with multiple sclerosis, um that isn't just a metaphor.
- 0:34SPEAKER_00: I mean, that is their daily biological reality.
- 0:37SPEAKER_01: Aaron Powell It's terrifying.
- 0:38SPEAKER_01: And well, we are incredibly glad you're joining us for this deep dive today because our mission is all about, you know, cutting through the noise.
- 0:44SPEAKER_00: Aaron Powell There's a lot of noise out there.
- 0:45SPEAKER_00: Trevor Burrus, Jr.
- 0:45SPEAKER_01: Oh, an absolute hurricane of hype, especially if you spend any time researching regenerative medicine online.
- 0:50SPEAKER_01: It can be, frankly, incredibly difficult to separate genuine scientific progress from like science fiction.
- 0:58SPEAKER_00: Aaron Powell It's a profound challenge for patients.
- 1:01SPEAKER_00: Absolutely.
- 1:01SPEAKER_00: When you're looking for answers about a complex chronic condition like MS, the sheer volume of conflicting information.
- 1:10SPEAKER_01: Miracle claims.
- 1:11SPEAKER_01: Yes.
- 1:12SPEAKER_00: The heavily marketed cures, it can be completely overwhelming.
- 1:15SPEAKER_00: You know, you really need an anchor in the actual science.
- 1:18SPEAKER_01: Aaron Powell, which is exactly why we're pulling from a very specific grounded stack of source material today.
- 1:23SPEAKER_01: We're looking through the comprehensive clinical guides and protocols from Cyrona Cell.
- 1:28SPEAKER_01: They are a uh doctor-led regenerative medicine and stem cell therapy center based over in Kuala Lumpur, Malaysia.
- 1:34SPEAKER_01: Aaron Powell Right.
- 1:35SPEAKER_01: And the core question we are putting under the microscope for you today is this For someone living with multiple sclerosis or MS, what can stem cell therapy actually achieve?
- 1:45SPEAKER_01: Like what are the realistic goals when it comes to managing fatigue, mobility, and uh relapse rates?
- 1:51SPEAKER_00: Aaron Ross Powell Well, right out of the gate, we have to establish the reality of what we're discussing here.
- 1:55SPEAKER_00: We are not um we're not looking at magic bullets to miracle cure.
- 1:59SPEAKER_00: Exactly.
- 1:59SPEAKER_00: We are looking at the hard clinical science of slowing down a really devastating disease.
- 2:05SPEAKER_00: It's about understanding the mechanics of the nervous system well enough to actually protect it.
- 2:10SPEAKER_01: Okay, let's unpack this.
- 2:11SPEAKER_01: Before we can even begin to understand how a high-tech treatment works, we kind of have to understand the battlefield, right?
- 2:17SPEAKER_01: So what is MS actually breaking inside the body?
- 2:21SPEAKER_00: Aaron Powell So to understand the disease, you have to look at the central nervous system, which is basically your brain and your spinal cord.
- 2:28SPEAKER_01: Okay.
- 2:28SPEAKER_00: MS is an autoimmune condition where that internal security system you mentioned uh goes rogue.
- 2:35SPEAKER_00: It mistakenly identifies the central nervous system as a foreign threat.
- 2:39SPEAKER_01: Like a virus or something.
- 2:40SPEAKER_00: Right.
- 2:41SPEAKER_00: But it doesn't just attack the tissue at random.
- 2:43SPEAKER_00: Yeah.
- 2:44SPEAKER_00: It specifically seeks out and destroys this structure called the myelin sheath.
- 2:49SPEAKER_01: Aaron Powell Yeah, I've seen that term a lot in these clinical notes.
- 2:51SPEAKER_01: The myelin is essentially like the protective coating wrapped around our nerve fibers.
- 2:55SPEAKER_00: You think of it as a specialized fatty insulation.
- 2:58SPEAKER_00: Its primary job is to make sure that the electrical signals sent from your brain travel smoothly and you know instantly to the rest of your body.
- 3:05SPEAKER_01: Makes sense.
- 3:06SPEAKER_00: But when the immune system attacks as myelin, it strips it away.
- 3:10SPEAKER_00: And that leaves behind all this inflammation and hard scars, which uh neurologists refer to as lesions.
- 3:16SPEAKER_01: And from what I'm gathering in the sources, the location of those lesions is basically everything.
- 3:20SPEAKER_01: It seems to dictate the entire patient experience.
- 3:23SPEAKER_00: Oh, location completely defines the symptoms.
- 3:27SPEAKER_00: If the immune system, say, strips the myelin near your motor pathways, your brain's command to move your leg gets lost in transit.
- 3:34SPEAKER_01: So you experience physical weakness or paralysis.
- 3:36SPEAKER_00: Exactly.
- 3:37SPEAKER_00: But if the damage happens along sensory pathways, the misfiring signals cause numbness or strange tingling or even severe nerve pain.
- 3:44SPEAKER_01: Wow.
- 3:45SPEAKER_00: And if it hits the cerebellum to the back of the brain, your coordination and balance just fall apart.
- 3:50SPEAKER_00: Because these lesions can form literally anywhere along the brain or spinal cord, no two patients will ever have the exact same journey with MSP.
- 3:58SPEAKER_01: Speaking of the journey, I'm noticing a really distinct trend in these cyrocilla guides.
- 4:03SPEAKER_01: I see these different acronyms popping up constantly, like RRMS, SPMS, PPMS.
- 4:09SPEAKER_01: Does the disease, I mean, actually change its entire strategy over time?
- 4:13SPEAKER_00: It does, yeah.
- 4:14SPEAKER_00: And understanding those phases is vital for, well, any treatment plan.
- 4:19SPEAKER_00: So the most common starting point is relapsing remitting MS or RRMS.
- 4:23SPEAKER_01: Okay, what does that look like?
- 4:24SPEAKER_00: This is where the immune system attacks in these aggressive ways or relapses, right?
- 4:28SPEAKER_00: It causes sudden new symptoms.
- 4:30SPEAKER_00: But then the attack subsides, the inflammation cools down, and the patient experiences a period of partial or sometimes complete recovery.
- 4:37SPEAKER_01: But I'm guessing that doesn't last forever.
- 4:39SPEAKER_00: Unfortunately, no.
- 4:40SPEAKER_00: Over time, the body's ability to recover wanes.
- 4:44SPEAKER_01: Which leads to the next phase in the notes, secondary progressive MS.
- 4:47SPEAKER_00: Correct.
- 4:47SPEAKER_00: In SPMS, the clear waves of attacks and recoveries basically stop.
- 4:51SPEAKER_00: Instead, the disease transitions into a slow, steady, continuous decline.
- 4:56SPEAKER_00: The damage just accumulates without those periods of relief.
- 4:59SPEAKER_01: And what about that third one?
- 5:00SPEAKER_01: PPMS.
- 5:01SPEAKER_00: Right.
- 5:01SPEAKER_00: Primary progressive MS kit.
- 5:04SPEAKER_00: It's rarer.
- 5:05SPEAKER_00: In PPMS, there are never any relapsing waves to begin with.
- 5:08SPEAKER_00: The steady neurological decline just begins on day one and it simply doesn't stop.
- 5:13SPEAKER_01: Man.
- 5:14SPEAKER_01: So to visualize this, the myelin is basically like the rubber insulation on a copper electrical wire.
- 5:20SPEAKER_01: When that rubber gets chewed up by the immune system, the electrical signal shorts out, or I guess slows down to a crawl.
- 5:25SPEAKER_01: Trevor Burrus, Jr.
- 5:26SPEAKER_01: That's a great way to picture it.
- 5:27SPEAKER_01: But I actually have to push back on this a bit.
- 5:28SPEAKER_01: Because if the wire is just stripped in one specific location, say, I have illusion affecting a sensory pathway in my arm, and my arm goes numb.
- 5:37SPEAKER_01: Why do so many MS patients describe this profound, like soul-crushing, full-body exhaustion?
- 5:44SPEAKER_01: Shouldn't a stripped wire in my arm just be a localized arm glitch?
- 5:48SPEAKER_01: Why the systemic exhaustion?
- 5:49SPEAKER_00: I'm so glad you brought that up because it gets to the absolute core of what living with MS actually feels like.
- 5:55SPEAKER_00: You're pointing out the localized physical damage, but we have to look at the invisible systemic toll of the disease.
- 6:01SPEAKER_01: Right.
- 6:01SPEAKER_00: This is where we enter the two-front war of MS crypt fatigue and mobility.
- 6:05SPEAKER_01: Aaron Powell Let's focus on the fatigue front first.
- 6:07SPEAKER_01: Because the clinical literature clearly states that while mobility loss is, you know, the most visible sign of MS to the outside world, the fatigue is what patients consistently say is the most debilitating part of their daily life.
- 6:20SPEAKER_00: Aaron Ross Powell We have to completely separate MS fatigue from normal tiredness.
- 6:25SPEAKER_00: Like a healthy person has a busy day, they get tired, they sleep, they recover.
- 6:29SPEAKER_01: Right.
- 6:29SPEAKER_01: Standard fatigue.
- 6:30SPEAKER_00: But MS fatigue is this deep metabolic exhaustion that you literally cannot just nap away.
- 6:37SPEAKER_00: And it has two distinct biological drivers.
- 6:39SPEAKER_00: First, go back to your stripwire analogy.
- 6:41SPEAKER_00: Because the insulation is gone, that specific nerve has to expend an immense amount of extra metabolic energy just to force a basic signal through the damaged area.
- 6:50SPEAKER_01: Oh wow.
- 6:51SPEAKER_01: It's like trying to drive a car on the highway with the emergency brake permanently pulled up.
- 6:55SPEAKER_00: Exactly.
- 6:55SPEAKER_01: The engine is just screaming, burning through a whole tank of gas just to go like 20 miles an hour.
- 7:00SPEAKER_00: That is a perfect way to picture it.
- 7:02SPEAKER_00: Your central nervous system is working on overdrive, burning massive energy reserves just to perform basic background functions that used to be completely effortless.
- 7:12SPEAKER_01: That sounds exhausting.
- 7:13SPEAKER_00: It is.
- 7:14SPEAKER_00: But there is a second driver of this fatigue, and it's the grueling strain of living with chronic systemic inflammation.
- 7:21SPEAKER_01: Because the immune system is constantly in attack mode, right?
- 7:24SPEAKER_00: Right.
- 7:24SPEAKER_00: Your body thinks it is fighting off a massive life-threatening infection day in and day out, even though there's no virus or bacteria there.
- 7:34SPEAKER_00: Have you ever had a severe case of the flu where just walking to the kitchen feels like running a marathon?
- 7:38SPEAKER_01: Yeah, absolutely.
- 7:39SPEAKER_01: Your body just aches.
- 7:41SPEAKER_00: That is your body diverting all your energy to your immune system.
- 7:44SPEAKER_00: MS patients are living with that internal inflammatory drain constantly.
- 7:48SPEAKER_01: Okay, so that perfectly explains the crushing fatigue.
- 7:51SPEAKER_01: But what about the mobility front?
- 7:53SPEAKER_01: Because the medical guidelines draw a very stark crucial line here regarding the actual nerve damage.
- 8:00SPEAKER_00: Yes.
- 8:00SPEAKER_00: This might be the most important anatomical distinction for a patient to really understand.
- 8:05SPEAKER_00: We have to separate demyelinated nerves from severed nerves.
- 8:09SPEAKER_01: Okay, break that down for us.
- 8:11SPEAKER_00: So if a nerve fiber is demyelinated, meaning the insulation is stripped away, but the physical copper wire underneath is still alive, the signals are dysfunctional, sure, but that nerve can potentially recover.
- 8:22SPEAKER_00: It's still viable.
- 8:23SPEAKER_00: Okay.
- 8:24SPEAKER_00: But if the nerve fiber itself has broken down and died due to prolonged exposure and damage, that physical loss is permanent.
- 8:32SPEAKER_01: Wow.
- 8:32SPEAKER_01: Okay.
- 8:33SPEAKER_01: So current medical science cannot regrow a dead central nervous system nerve.
- 8:37SPEAKER_00: What's fascinating here is how accepting this reality fundamentally shifts the entire goal of medical treatment.
- 8:44SPEAKER_00: How so?
- 8:44SPEAKER_00: The goal isn't to magically resurrect dead nerves.
- 8:48SPEAKER_00: The goal is to fiercely protect the nerves that are currently under siege.
- 8:51SPEAKER_00: We have to stop the active inflammation before demyelination turns into prominent nerve death.
- 8:56SPEAKER_01: Okay, let me synthesize this to make sure I'm putting the pieces together correctly for you listening.
- 9:00SPEAKER_01: If the actual physical wire is snapped, mobility is gone.
- 9:04SPEAKER_01: There's no fixing that wire today.
- 9:05SPEAKER_01: Right.
- 9:06SPEAKER_01: But if the wire is just stripped and the room around it is basically on fire with active inflammation, we might actually be able to put the fire out, save the wire, and give the body a chance to patch the insulation.
- 9:18SPEAKER_00: That is the exact clinical objective.
- 9:20SPEAKER_00: Putting out the fire is everything.
- 9:22SPEAKER_01: Right.
- 9:22SPEAKER_01: But if the goal is just to put out the fire before the wire snaps, how do we actually do that?
- 9:26SPEAKER_01: Because standard daily medications don't seem to stop the progression entirely for everyone.
- 9:31SPEAKER_00: They don't, no.
- 9:32SPEAKER_01: Looking at the research, there are two major stem cell strategies currently in play.
- 9:36SPEAKER_01: Let's start with the aggressive one, HSCT.
- 9:39SPEAKER_00: Oh yes.
- 9:40SPEAKER_00: HSCT stands for hemetopoietic stem cell transplant.
- 9:44SPEAKER_00: This is typically reserved for highly active, severe relapsing remitting MS.
- 9:49SPEAKER_00: And the mechanism here is extreme.
- 9:52SPEAKER_01: Extreme how?
- 9:53SPEAKER_00: It involves extracting the patient's own blood-forming stem cells and then using intense high-dose chemotherapy to completely eradicate the patient's existing immune system.
- 10:02SPEAKER_01: Wait, they just wipe the entire immune system out?
- 10:04SPEAKER_01: That sounds terrifying.
- 10:05SPEAKER_00: It is a massive undertaking.
- 10:07SPEAKER_00: The goal is to basically destroy the faulty immune cells that are attacking the myelin.
- 10:12SPEAKER_00: Once the immune system is wiped blank, doctors reintroduce the safe stem cells to rebuild a brand new immune system from scratch.
- 10:19SPEAKER_01: Oh, I see.
- 10:20SPEAKER_00: One that ideally does not have the memory or the programming to attack the nervous system.
- 10:25SPEAKER_01: So HSCT is essentially bulldozing the burning house to the ground, pouring a brand new foundation, and just hoping the new builders don't use the same flawed blueprints.
- 10:34SPEAKER_00: Aaron Powell That's a very accurate way to look at it, actually.
- 10:37SPEAKER_00: It is highly effective at stopping violent relapses.
- 10:40SPEAKER_00: But um it requires weeks of isolation in a hospital because you have zero immune defenses.
- 10:46SPEAKER_01: Yeah.
- 10:46SPEAKER_00: And it carries severe risks from the chemotherapy itself.
- 10:49SPEAKER_01: Aaron Powell Right.
- 10:49SPEAKER_01: That's a huge toll on the body.
- 10:51SPEAKER_00: Aaron Powell Exactly.
- 10:52SPEAKER_00: Which is why the clinical guides from Cyrona cell focus much more heavily on the second approach, MSCs or mesenchymal stem cells.
- 10:59SPEAKER_01: Right.
- 10:59SPEAKER_01: So if HSCT is the bulldozer, how do MSCs operate?
- 11:03SPEAKER_01: Are they like bringing in a highly trained hostage negotiator?
- 11:06SPEAKER_00: Aaron Ross Powell A biological mediator, yes.
- 11:08SPEAKER_00: Exactly.
- 11:09SPEAKER_00: MSC therapy does not involve chemotherapy, and it definitely doesn't destroy your immune system.
- 11:14SPEAKER_01: Okay, that's a relief.
- 11:16SPEAKER_00: Instead, millions of these specialized stem cells are introduced into the body.
- 11:20SPEAKER_00: Once there, they detect the chaotic burning room of your immune system and they start releasing specific molecules.
- 11:27SPEAKER_01: What do the molecules do?
- 11:28SPEAKER_00: They act as chemical signals that essentially tell the aggressive immune cells to stand down and stop attacking.
- 11:34SPEAKER_01: They change the environment from a war zone to a ceasefire.
- 11:37SPEAKER_00: Exactly.
- 11:38SPEAKER_00: They drastically reduce that bodywide inflammation.
- 11:41SPEAKER_00: And crucially, MSCs also release specific growth factors that support the brain's native repair cells.
- 11:47SPEAKER_01: Oh, so they actually help with repair.
- 11:49SPEAKER_00: Yes, encouraging them to produce new myelin and patch up those strip wires, a process called remyelination.
- 11:56SPEAKER_01: Okay, but I have to ask the obvious question here.
- 11:58SPEAKER_01: If MSCs are safer, if there's no chemotherapy, no bulldozing the immune system, and no weeks in an isolation award, why isn't every single MS patient just doing MSC therapy?
- 12:08SPEAKER_01: What is the catch when it comes to the actual results?
- 12:11SPEAKER_00: The catch really comes down to setting extremely realistic expectations based on the severity and the phase of the disease.
- 12:18SPEAKER_00: Okay.
- 12:18SPEAKER_00: MSCs are brilliant at calming inflammation and protecting surviving nerves.
- 12:23SPEAKER_00: But they are not the heavy sledgehammer that HSCT is for halting the most violent, aggressive relapses in a really young patient.
- 12:31SPEAKER_00: This brings us directly back to the core mission of our deep dive today.
- 12:36SPEAKER_00: What are the actual realistic goals for a patient doing MSE therapy?
- 12:40SPEAKER_01: Let's look at the data on that.
- 12:41SPEAKER_01: According to the research, what does success actually look like?
- 12:45SPEAKER_01: Because the most irrefutable, well-documented benefit seems to be a significant drop in relapse rates.
- 12:50SPEAKER_00: Yeah, the clinical evidence is clear that stem cell treatments are most effective during the active inflammatory stages of MSC cough.
- 12:58SPEAKER_00: Exactly.
- 12:59SPEAKER_00: When you bring in MSCs to quiet that active disease, patients typically experience fewer relapses, and MRI scans actually show fewer new lesions forming.
- 13:07SPEAKER_01: That's huge.
- 13:08SPEAKER_00: It is.
- 13:09SPEAKER_00: And because that systemic inflammation drops so dramatically, patients often see a very real tangible improvement in that grueling metabolic fatigue we talked about earlier.
- 13:18SPEAKER_01: But the clinical literature gets, well, much more somber when we look at secondary progressive MS.
- 13:24SPEAKER_01: SPMS seems to be the absolute hardest phase of the disease to treat.
- 13:29SPEAKER_00: Aaron Powell It is the hardest phase, yes.
- 13:31SPEAKER_00: And it relates right back to our wire analogy.
- 13:33SPEAKER_00: By the time a patient is deep into SPMS, their disability is no longer primarily driven by active waves of inflammation.
- 13:39SPEAKER_01: Aaron Ross Powell Because the damage is already done.
- 13:41SPEAKER_00: Right.
- 13:42SPEAKER_00: Their disability comes from the fixed permanent loss of those nerve fibers.
- 13:46SPEAKER_00: The wires have already snapped.
- 13:48SPEAKER_01: And like we said, you can't fix a snapped wire.
- 13:50SPEAKER_00: Exactly.
- 13:50SPEAKER_00: Stem cells cannot bridge a fully severed gap in the spinal cord.
- 13:54SPEAKER_00: Because of this, you do not see massive, miraculous improvements in their ability to walk, for instance.
- 14:00SPEAKER_01: Aaron Powell So does the medical community just throw their hands up?
- 14:03SPEAKER_01: Like does MSc therapy still have a role for someone with SPMS?
- 14:07SPEAKER_00: It absolutely has a role.
- 14:08SPEAKER_00: Even in SPMS, there's still a low-grade smoldering undercurrent of continuous inflammation causing damage.
- 14:14SPEAKER_00: MSCs can still target and reduce that remaining fire.
- 14:18SPEAKER_00: It might not help a patient run a marathon again, but by cooling that inflammation, it can improve bladder function, reduce nerve pain, lessen the daily fatigue, and crucially slow down the progression of the disease.
- 14:30SPEAKER_01: It provides stability.
- 14:32SPEAKER_00: Yes, it provides stability.
- 14:34SPEAKER_01: Let's compare this to the standard route for a second.
- 14:36SPEAKER_01: Most patients are on DMTs disease modifying therapies, which are, you know, daily pills or regular injections.
- 14:43SPEAKER_01: How is an MSC stem cell infusion fundamentally different from just taking your standard DMTs?
- 14:48SPEAKER_00: It's really a difference in the biological mechanism.
- 14:50SPEAKER_00: Standard DMTs require continuous ongoing suppression of the immune system.
- 14:54SPEAKER_01: Like you have to keep taking them forever.
- 14:56SPEAKER_00: Right.
- 14:57SPEAKER_00: The moment you stop taking the drug, the suppression lifts and the attacks usually resume.
- 15:01SPEAKER_01: NMSCs.
- 15:02SPEAKER_00: MSCs, however, are aiming to permanently, or at least long term, shift the immune environment itself.
- 15:07SPEAKER_01: Oh, fascinating.
- 15:08SPEAKER_00: The cells themselves only survive in the body for a short time, maybe a few months.
- 15:14SPEAKER_00: But the immunomodulatory signals they release create a kind of a reset effect in the immune environment that can last well beyond the actual treatment.
- 15:23SPEAKER_01: So, what does this all mean for the patient?
- 15:25SPEAKER_01: Let me challenge the entire concept of success for a second here.
- 15:28SPEAKER_01: For a patient who has been watching their body slowly betray them for a decade, losing a little more function every single year, is stability just stopping the decline, keeping things exactly as difficult as they are right now?
- 15:42SPEAKER_01: Is that really the win we're looking for, or is that like a bitter pill to swallow when you hear the futuristic promise of stem cells?
- 15:49SPEAKER_00: It can be incredibly difficult to accept initially, because human nature desperately wants a cure.
- 15:54SPEAKER_00: We want a time machine to take us back ten years.
- 15:57SPEAKER_01: Right, of course.
- 15:57SPEAKER_00: But from a clinical neurological perspective, stopping the decline of a progressive degenerative disease is a monumental medical victory.
- 16:06SPEAKER_01: Wow.
- 16:06SPEAKER_01: Put that way.
- 16:07SPEAKER_00: Yeah.
- 16:07SPEAKER_00: Halting a disease that is genetically programmed to slowly strip away your independence is extraordinary.
- 16:13SPEAKER_00: Stability means you keep the ability to feed yourself, you keep the ability to transfer from your bed to a chair, you keep your voice.
- 16:21SPEAKER_01: Yeah.
- 16:22SPEAKER_00: In the realm of progressive neurology, stability is everything.
- 16:26SPEAKER_01: Aaron Powell That is a remarkably powerful way to frame it.
- 16:29SPEAKER_01: And the fact that stability can be achieved safely brings us to the actual execution of these treatments.
- 16:34SPEAKER_01: Because the global landscape of stem cell clinics is, frankly, famously described as the Wild West.
- 16:40SPEAKER_00: Oh, absolutely.
- 16:41SPEAKER_01: You have clinics promising to cure everything from MS to baldness with zero oversight.
- 16:46SPEAKER_00: Aaron Powell It is a massive problem in the industry, and it preys on desperate patients.
- 16:50SPEAKER_00: That is why examining a structured, regulated protocol like the one at Cyrona Cell in Kuala Lumpur is so instructive for understanding how this should be done.
- 16:58SPEAKER_01: Yeah, and I actually found the name fascinating.
- 17:00SPEAKER_01: Cyrona is named after an ancient Celtic goddess of health, healing, and protection.
- 17:05SPEAKER_01: Aaron Powell.
- 17:06SPEAKER_01: The sources highlight that this name reflect their entire medical ethos, prioritizing absolute safety over quick fix, exaggerated promises.
- 17:14SPEAKER_00: Aaron Powell And you see that protection ethos in the specific science they choose to utilize.
- 17:20SPEAKER_00: They use ethically sourced umbilical cord-derived cells.
- 17:24SPEAKER_01: Right, I'm looking at the specific terminology they use here, and it says they utilize early passage WJMSCs.
- 17:30SPEAKER_01: What on earth does WJ stand for?
- 17:32SPEAKER_00: That stands for Wharton's Jelly.
- 17:34SPEAKER_01: Wharton's jelly.
- 17:35SPEAKER_00: Sounds a bit strange, I know.
- 17:36SPEAKER_01: Yeah.
- 17:37SPEAKER_00: But it is a natural gelatinous tissue found inside the human umbilical cord.
- 17:41SPEAKER_00: It is incredibly rich in pristine, highly active mesenchymal stem cells.
- 17:47SPEAKER_01: Okay, and where do they get it?
- 17:49SPEAKER_00: Sorona cell obtains these from healthy, full-term deliveries with the explicit ethical consent of the donor mothers.
- 17:56SPEAKER_00: They are day zero cells with massive vitality.
- 17:59SPEAKER_01: Well, why not just use the patient's own stem cells?
- 18:02SPEAKER_01: I know a lot of clinics extract fat or bone marrow from the patient to get cells.
- 18:06SPEAKER_00: Because with an autoimmune condition like MS, the patient's own cells have been living in a diseased inflammatory environment for years.
- 18:13SPEAKER_01: Oh, that makes sense.
- 18:14SPEAKER_00: Yeah, they often carry what we call epigenetic markers.
- 18:17SPEAKER_00: Think of these markers as biological switches that have been flipped to the disease position.
- 18:22SPEAKER_00: If you use the patient's own cells, you risk reintroducing cells that are already primed to act dysfunctional.
- 18:28SPEAKER_00: Using healthy donor WJMSCs bypasses that problem entirely.
- 18:33SPEAKER_01: The clinic notes also drop a massive list of laboratory certifications like BSL2, CGMP, ISO 9001.
- 18:41SPEAKER_01: Honestly, as a layman, my eyes usually glaze over when I see a wall of regulatory acronyms.
- 18:47SPEAKER_01: What do those actually mean for my safety?
- 18:50SPEAKER_00: Which is completely fair.
- 18:51SPEAKER_00: But for a patient, those acronyms are your safety net.
- 18:54SPEAKER_01: Okay.
- 18:54SPEAKER_00: BSL2 refers to the strict biosafety level of their laboratories, ensuring the air and environment are highly controlled to prevent any contamination.
- 19:02SPEAKER_01: Good to know.
- 19:03SPEAKER_01: And CGMP.
- 19:04SPEAKER_00: CGMP stands for current good manufacturing practice.
- 19:08SPEAKER_00: In simple terms, it means they have a process that guarantees every single batch of cells is identical in identity, sterility, and viability.
- 19:15SPEAKER_01: So you're not just getting a random soup of cells.
- 19:17SPEAKER_00: Exactly.
- 19:17SPEAKER_00: You know exactly what dose you were getting and you know it is clean.
- 19:20SPEAKER_00: When you're introducing biological material directly into a patient's bloodstream, that level of control is simply non-negotiable.
- 19:27SPEAKER_01: But almost more important than what they do is what they explicitly refuse to do.
- 19:31SPEAKER_01: The documents make it abundantly clear.
- 19:34SPEAKER_01: They never use embryonic stem cells, and they never use experimental pluripotent stem cells.
- 19:40SPEAKER_00: This is a crucial safety boundary.
- 19:49SPEAKER_00: Bone, hair, teeth, heart muscle.
- 19:51SPEAKER_00: Sounds great in theory, but if you introduce them into a human body without perfect flawless programming, they just start growing wildly and uncontrollably.
- 20:00SPEAKER_00: And a mass of wildly growing, uncontrolled cells is essentially the definition of a tumor.
- 20:05SPEAKER_01: Jeez.
- 20:06SPEAKER_01: So by sticking strictly to mesenchymal stem cells or WJMSCs, they avoid that risk entirely.
- 20:12SPEAKER_00: Yes.
- 20:12SPEAKER_00: WJMSCs have a very well-documented decades-long safety profile.
- 20:16SPEAKER_00: They do their job of immunomodulation, calming the immune system, and then they naturally clear from the body without carrying that severe tumor risk.
- 20:23SPEAKER_01: That is reassuring.
- 20:24SPEAKER_00: Furthermore, Cyronacell administers these therapies through minimally invasive routes, like targeted injections or simple IV infusions.
- 20:32SPEAKER_00: There is no major open surgery involved in their standard MS protocols.
- 20:38SPEAKER_01: As I was reading through all this, the thing that stood out to me most wasn't even the science, honestly.
- 20:42SPEAKER_01: It was the refreshing honesty of their medical team.
- 20:45SPEAKER_01: They have a full board of neurologists, internal medicine physicians, and rehabilitation specialists.
- 20:51SPEAKER_01: And they state point blank that they are committed to telling patients no.
- 20:55SPEAKER_00: Which is rare in this industry.
- 20:57SPEAKER_01: Right.
- 20:57SPEAKER_01: If they look at your MRI and see that your nerves are fully degraded, and you tell them your goal is to run a marathon, they will turn you away because the therapy is not appropriate for you.
- 21:06SPEAKER_00: If we connect this to the bigger picture of modern medicine, this is exactly why regenerative treatments must always be an adjunct to specialist care, not a rogue replacement for it.
- 21:16SPEAKER_01: Right.
- 21:17SPEAKER_00: True medical professionals will coordinate with your existing neurologist.
- 21:20SPEAKER_00: They track your outcomes, they monitor for side effects, and they prioritize long-term clinical trust over making a quick buck on a one-time procedure.
- 21:28SPEAKER_01: As it should be.
- 21:29SPEAKER_00: That is the standard of care the entire regenerative field needs to be held to.
- 21:33SPEAKER_01: Well, we have covered a tremendous amount of ground today.
- 21:36SPEAKER_01: To quickly recap the journey for you listening, multiple sclerosis is a devastating autoimmune attack where the body's internal security system basically chews up the nervous system's wiring.
- 21:46SPEAKER_01: Right.
- 21:47SPEAKER_01: The true daily enemies for a patient aren't just the visible mobility issues, they are the profound metabolic fatigue and the unpredictable relapses.
- 21:56SPEAKER_01: And while the internet might promise magic, the true role of therapies like WJMSEs is highly specific and grounded.
- 22:04SPEAKER_00: Highly grounded.
- 22:04SPEAKER_01: They act as biological mediators to calm the fire of systemic inflammation.
- 22:09SPEAKER_01: They aim to stop the active damage, fiercely protect the surviving nerves, and offer a real chance at long-term stability.
- 22:16SPEAKER_00: It is about fundamentally shifting our focus from trying to reverse the irreversible to fiercely protecting what remains and optimizing the body's internal environment for whatever natural repair it can still actually manage.
- 22:29SPEAKER_01: Exactly.
- 22:30SPEAKER_01: And to you listening, whether you are navigating an MS diagnosis yourself or trying to help a loved one research their options, understanding this underlying science changes everything.
- 22:41SPEAKER_01: It really does.
- 22:42SPEAKER_01: Understanding the critical difference between a nerve that is actively inflamed and a nerve that is permanently damaged changes how you evaluate treatments.
- 22:50SPEAKER_01: It gives you the vocabulary to see past the marketing hype, ask your medical team the right questions, and truly advocate for the care you deserve.
- 22:58SPEAKER_00: I want to leave you with a final lingering idea to ponder as we wrap up today's deep dive.
- 23:04SPEAKER_00: Go for it.
- 23:04SPEAKER_00: For the last century, we have spent so much time in modern medicine trying to aggressively attack and kill diseases from the outside.
- 23:12SPEAKER_00: We use harsh chemotherapies, we use heavy immune suppressants, we basically bulldoze the house to save the neighborhood.
- 23:19SPEAKER_00: Right.
- 23:19SPEAKER_00: But what if the true future of treating complex autoimmune conditions isn't about fighting our bodies at all?
- 23:25SPEAKER_00: What if the future is simply learning how to give our own cells the precise molecular signals they need to finally put down their weapons and heal themselves?